🇺🇸 Rotigotine PR 2.2.1 in United States

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FDA authorised Rotigotine PR 2.2.1 on 9 May 2007

Marketing authorisation

FDA — authorised 9 May 2007

Application: NDA021829
Marketing authorisation holder: UCB INC
Local brand name: NEUPRO
Indication: FILM, EXTENDED RELEASE — TRANSDERMAL
Status: approved

Read official source →

Frequently asked questions

Is Rotigotine PR 2.2.1 approved in United States?

Yes. FDA authorised it on 9 May 2007.

Who is the marketing authorisation holder for Rotigotine PR 2.2.1 in United States?

UCB INC holds the US marketing authorisation.